Focus: Owkin is an AI-focused biotechnology company headquartered in New York specializing in applying machine learning to medical research across neurology, oncology, and gastroenterology.
Profile data last refreshed 14h ago · AI intelligence enriched 2mo ago
No open roles listed right now. Follow Owkin to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from Owkin's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Owkin
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Owkin licenses AI scientist, patient data to Servier for oncology research - MobiHealthNews
Owkin licenses AI scientist, patient data to Servier for oncology research MobiHealthNews
Owkin Licenses K Pro AI Scientist And Multimodal Patient Data To Servier For Oncology Research - Pulse 2.0
Owkin Licenses K Pro AI Scientist And Multimodal Patient Data To Servier For Oncology Research Pulse 2.0
Owkin to License K Pro and Multimodal Data to Servier to Advance Oncology Research - Business Wire
Owkin to License K Pro and Multimodal Data to Servier to Advance Oncology Research Business Wire
Owkin Partners with Boehringer Ingelheim to Accelerate Drug Discovery with AI - SynBioBeta
Owkin Partners with Boehringer Ingelheim to Accelerate Drug Discovery with AI SynBioBeta
Boehringer Ingelheim signs AI agreement with Owkin - medwatch.com
Boehringer Ingelheim signs AI agreement with Owkin medwatch.com
Owkin licenses AI Scientist platform and multimodal patient data to Boehringer - The Pharma Letter
Owkin licenses AI Scientist platform and multimodal patient data to Boehringer The Pharma Letter
Showing 6 of 10 news items
No open positions listed yet. Check their careers page directly.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moBased on last 4 crawl cycles
Recent peer-reviewed publications with author affiliations at this company
Showing 5 of 10 publications